USP7-Dependent Regulation of TRAF Activation and Signaling by a Viral Interferon Regulatory Factor Homologue.

TRAF3 TRAF6 herpesvirus-associated ubiquitin-specific protease human herpesvirus 8 latency replication tumor necrosis factor receptor-associated factors ubiquitin-specific protease 7 viral interferon regulatory factor-2

Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
06 01 2020
Historique:
received: 11 09 2019
accepted: 22 10 2019
pubmed: 2 11 2019
medline: 10 6 2020
entrez: 1 11 2019
Statut: epublish

Résumé

Human herpesvirus 8 (HHV-8) encodes four viral interferon regulatory factors (vIRFs 1 to 4), all of which are expressed during lytic replication and inhibit a variety of antiviral signaling pathways. Viral IRFs 1, 2, and 3 are also expressed during latency in primary effusion lymphoma (PEL) cells, and vIRF-1 and vIRF-3 have been reported to promote PEL cell viability. Viral IRFs 1, 3, and 4 are known to interact with ubiquitin-specific protease 7 (USP7); interactions of vIRF-1 and vIRF-3 with USP7 promote PEL cell viability and regulate productive replication. Here, we report that vIRF-2 also targets USP7, utilizing a PSTS motif matching the USP7 N-terminal domain-binding A/PxxS consensus, but uniquely requires catalytic domain residues for intracellular interaction. In functional and mechanistic analyses, tumor necrosis factor receptor-associated factor (TRAF)-mediated signaling and associated polyubiquitination of TRAFs 3 and 6, specifically, were regulated negatively by USP7 and positively by vIRF-2-USP7 interaction, the latter competing for USP7-TRAF association. Using depletion, depletion-complementation, and targeted mutagenesis approaches, vIRF-2 was determined to promote latent PEL cell viability, likely independently of USP7 interaction, while lytic replication was inhibited by vIRF-2, in part or in whole via USP7 interaction. Together, our data identify a new molecular determinant of USP7 recognition, TRAF3/6-specific targeting by the deubiquitinase, associated activation of these TRAFs by vIRF-2, and activities of vIRF-2 and vIRF-2-USP7 interaction in HHV-8 latent and lytic biology.

Identifiants

pubmed: 31666375
pii: JVI.01553-19
doi: 10.1128/JVI.01553-19
pmc: PMC6955280
pii:
doi:

Substances chimiques

Interferon Regulatory Factors 0
Intracellular Signaling Peptides and Proteins 0
TNF Receptor-Associated Factor 3 0
TRAF3 protein, human 0
Tifab protein, human 0
Viral Proteins 0
viral interferon regulatory factors 0
USP7 protein, human EC 3.4.19.12
Ubiquitin-Specific Peptidase 7 EC 3.4.19.12

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI140855
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA196348
Pays : United States

Informations de copyright

Copyright © 2020 Xiang et al.

Références

Blood. 2009 Apr 2;113(14):3264-75
pubmed: 18952891
J Neurosci. 2005 Feb 23;25(8):2002-9
pubmed: 15728840
J Biol Chem. 2009 Mar 27;284(13):8525-38
pubmed: 19129183
J Virol. 1999 Oct;73(10):8268-78
pubmed: 10482577
J Gen Virol. 2003 Jun;84(Pt 6):1471-83
pubmed: 12771416
PLoS Pathog. 2019 May 6;15(5):e1007743
pubmed: 31059555
J Virol. 2003 Apr;77(7):4205-20
pubmed: 12634378
J Virol. 2009 Jul;83(13):6739-47
pubmed: 19369353
J Virol. 2012 Sep;86(18):9708-20
pubmed: 22740391
EMBO J. 2007 Sep 5;26(17):3910-22
pubmed: 17703191
J Biol Chem. 2016 Mar 18;291(12):6281-91
pubmed: 26786098
PLoS Pathog. 2018 May 10;14(5):e1007058
pubmed: 29746593
J Mol Signal. 2013 Jun 13;8(1):7
pubmed: 23758787
J Hum Virol. 1999 Jan-Feb;2(1):19-32
pubmed: 10200596
J Biol Chem. 2001 Jun 29;276(26):24242-52
pubmed: 11279055
J Virol. 2018 Mar 14;92(7):
pubmed: 29343584
Mol Cell Biol. 2014 Feb;34(3):386-99
pubmed: 24248600
Curr Opin Infect Dis. 2011 Aug;24(4):295-301
pubmed: 21666458
J Biol Chem. 2003 Aug 8;278(32):29987-94
pubmed: 12783858
Methods Mol Biol. 2010;634:421-30
pubmed: 20677001
J Biol Chem. 2009 Aug 28;284(35):23272-85
pubmed: 19553679
EMBO J. 2010 Aug 4;29(15):2553-65
pubmed: 20601937
Biotechniques. 2006 Feb;40(2):191-7
pubmed: 16526409
Oncogene. 2004 Aug 12;23(36):6146-55
pubmed: 15208654
Oncogene. 2001 Feb 15;20(7):800-11
pubmed: 11314014
Nat Struct Mol Biol. 2011 Nov 06;18(12):1336-44
pubmed: 22056774
Int J Cancer. 2015 Jul 15;137(2):251-61
pubmed: 24771491
J Virol. 2007 Aug;81(15):8282-92
pubmed: 17522209
J Virol. 2001 Jul;75(13):6193-8
pubmed: 11390621
Front Microbiol. 2012 Mar 02;3:73
pubmed: 22403576
J Virol. 2001 Mar;75(5):2345-52
pubmed: 11160738
J Interferon Cytokine Res. 2009 Sep;29(9):621-7
pubmed: 19715458
J Virol Methods. 2011 Jun;174(1-2):12-21
pubmed: 21419799
J Virol. 2015 Oct 28;90(1):506-20
pubmed: 26512076
J Virol. 2015 May;89(9):4918-31
pubmed: 25694600
Biochem Biophys Res Commun. 2016 Feb 12;470(3):650-656
pubmed: 26797279
J Virol. 2006 Mar;80(6):3092-7
pubmed: 16501120
J Virol. 2001 Jan;75(1):429-38
pubmed: 11119611
Oncogene. 1997 Oct 16;15(16):1979-85
pubmed: 9365244
J Mol Cell Biol. 2017 Feb 1;9(1):45-52
pubmed: 27927749
Curr Opin HIV AIDS. 2017 Jan;12(1):47-56
pubmed: 27662501
Eur J Cancer. 2001 Jul;37(10):1251-69
pubmed: 11423257
PLoS Biol. 2006 Feb;4(2):e27
pubmed: 16402859
Nat Struct Mol Biol. 2006 Mar;13(3):285-91
pubmed: 16474402
J Virol. 2012 Jun;86(12):6745-57
pubmed: 22514345
Biochem Biophys Res Commun. 2000 Apr 2;270(1):23-7
pubmed: 10733899
FASEB J. 2018 Oct;32(10):5238-5249
pubmed: 29688809
J Virol. 2006 Mar;80(5):2257-66
pubmed: 16474133
Hum Vaccin Immunother. 2014;10(11):3270-85
pubmed: 25625930
J Virol. 2000 Nov;74(21):10187-93
pubmed: 11024147
J Virol. 2017 Oct 27;91(22):
pubmed: 28878084
Biol Chem. 2017 Jul 26;398(8):857-870
pubmed: 28455950
J Virol. 2015 Aug;89(15):7979-90
pubmed: 26018151
J Mol Biol. 2010 Oct 8;402(5):825-37
pubmed: 20713061
PLoS Pathog. 2010 Aug 05;6(8):e1001031
pubmed: 20700448
Genes Dev. 2013 Feb 1;27(3):274-87
pubmed: 23388826
J Virol. 2009 Jan;83(2):722-33
pubmed: 18987143
J Virol. 2013 Sep;87(17):9398-410
pubmed: 23785197
Nature. 2008 Oct 2;455(7213):674-8
pubmed: 18724357
J Mol Biol. 2017 Nov 10;429(22):3395-3408
pubmed: 28591556
J Virol. 1999 Sep;73(9):7334-42
pubmed: 10438822
J Virol. 2001 Aug;75(16):7572-82
pubmed: 11462029
Transl Cancer Res. 2016 Dec;5(6):707-724
pubmed: 28690977
PLoS Pathog. 2012;8(6):e1002748
pubmed: 22685405

Auteurs

Qiwang Xiang (Q)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Hyunwoo Ju (H)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

John Nicholas (J)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA nichojo@jhmi.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH